Telix and FDA Agree Resubmission Pathway for Pixclara NDA
Filed with ASX · · 3 pages · English
Watch Telix Pharmaceuticals' latest callTelix Pharmaceuticals (ASX:TLX) Q2 2026 Earnings Call · Replay · Aug 20Read the transcript of Telix Pharmaceuticals (ASX:TLX) Q2 2026 Earnings CallTelix Pharmaceuticals Limited on 6ix
Earlier from Telix Pharmaceuticals
- Telix Provides Regulatory Update on TLX250-CDx
- Telix to Present at the Morgan Stanley 23rd Annual Global Healthcare Conference and H.C. Wainwright 27th Annual Global Investment Conference
- Telix H1 2025 Results Announcement
- Telix H1 2025 Results Presentation
- Telix H1 2025 Appendix 4D and Interim Report
Later from Telix Pharmaceuticals
- Telix Doses First Patient in Phase 3 BiPASS Trial: PSMA-PET Imaging for Prostate Cancer Diagnosis
- CMS Grants Transitional Pass-Through Status for Gozellix
- Telix Announces Record-Breaking Presence at EANM 2025
- Telix Reports US$206M Revenue, FY 2025 Guidance Upgraded
- TLX250-CDx (Zircaix®) Included in Leading International Guidelines for Renal Imaging
Follow Telix Pharmaceuticals into a list and get an email when it puts out news.
Follow Telix Pharmaceuticals